WHAT: National Institute on Aging (NIA) experts will be available to share some key latest accomplishments and advancements at the 12th Annual International Conference on Clinical Trials for Alzheimer's Disease (CTAD). Organized and planned by Alzheimer's disease and related dementias (AD/ADRD) clinical researchers to share scientific information with each other, this year's meeting will include a keynote presentation by the NIA Division of Neuroscience Director Dr. Eliezer Masliah on the state of AD/ADRD clinical trials and drug target discoveries.
Other topics include:
- The latest efforts on recruiting and retaining research participants, including plans from the National Strategy for Recruitment and Participation in Alzheimer's and Related Dementias Clinical Research and Alzheimer's Disease Research Centers
- The wide range of possible interventions and therapies (both pharmacologic and non-pharmacologic) including blood pressure control and exercise, immunotherapeutics, BACE inhibitors, and combination approaches
- The latest advances in developing blood-based biomarkers and other early tests for disease, for example mobile phone-based cognitive assessments
- New and existing resources and infrastructure for research (see list below), including open science, big data, data sharing, artificial intelligence and machine learning
NIA, part of the U.S. National Institutes of Health, is the single largest public funder of AD/ADRD research in the U.S. Through its multi-pronged approach, NIA currently is supporting about 230 active clinical trials as well as innovative research to prime and redesign drug discovery for these devasting diseases.
NIA experts will be available for interviews December 4-7 in person at CTAD, 1 Park Blvd, San Diego, California.
- Eliezer Masliah, M.D., director, Division of Neuroscience, NIA
- Laurie Ryan, Ph.D., chief, Dementias of Aging Branch, Division of Neuroscience, NIA
- Nina Silverberg, Ph.D., director, Alzheimer's Disease Research Centers Program, Division of Neuroscience, NIA
- Kristina McLinden, Ph.D., program officer, Division of Neuroscience, NIA
NIA-SUPPORTED PRESENTATION HIGHLIGHTS:
Following is a quick overview of NIA's CTAD role, including its supported research; please note, this research is embargoed until the start of the presentations:
- KEYNOTE by Dr. Masliah: "Overview of the NIA portfolio in AD clinical trials: Which new targets could be explored?" Thursday, Dec. 5, 1:30 - 2 p.m. Pacific Time
- "New Results on the Relationship between Intensive Blood Pressure Control and Cognitive Function from SPRINT-MIND" Wednesday, Dec. 4, 5 - 5:45 p.m. Pacific Time
- "One-month oral treatment with PTI-125, a new drug candidate, reduces CSF and plasma biomarkers of Alzheimer's disease" Thursday, Dec. 5, 6 - 6:15 p.m. Pacific Time
- "The EXERT Trial: Testing a Model for Effective Community-Based Exercise Intervention Delivery for Adults with MCI" Friday, Dec. 6, 2:15 - 2:30 p.m. Pacific Time
- "Alzheimer's Disease in Down Syndrome: New Insights and Opportunities" Saturday, Dec. 7, 10:45 - 11:30 a.m. Pacific Time
- "HOPE4MCI Trial: Targeting Reduction of Hippocampal Overactivity to Treat Mild Cognitive Impairment due to Alzheimer's Disease with AGB101" Saturday, Dec. 7, 2:15 - 2:30 p.m. Pacific Time
NIA-Funded Active Alzheimer's and Related Dementias Clinical Trials and Studies: https:/
NIA resources and infrastructure for research:
- Alzheimer's Clinical Trials Consortium (ACTC) - A clinical trials infrastructure designed to accelerate and expand studies for therapies in Alzheimer's disease and related dementias
- Alzheimer's Biomarkers Consortium - Down Syndrome (ABC-DS) - A joint study conducted by two groups of research collaborators exploring the connection between Down syndrome and Alzheimer's disease.
- Alzheimer's Disease Research Centers (ADRCs) - Research hubs working to translate scientific discoveries into improved diagnosis and care, as well as to find ways to treat and possibly prevent Alzheimer's disease and related dementias.
- Alzheimer's Disease Neuroimaging Initiative - An ongoing, longitudinal, multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer's disease.
- National Alzheimer's Coordinating Center (NACC) - A research data hub that has developed and maintains a large relational database of standardized clinical and neuropathological information freely available to researchers.
- National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD) - A research resource where clinical information and biological materials, such as DNA, plasma, serum, RNA, CSF, cell lines and brain tissue can be stored and requested.
- NIA Genetics of Alzheimer's Disease Data Storage Site (NIAGADS) - A national genetics repository created by NIA to facilitate access by qualified investigators to genotypic data for the study of genetics of late-onset Alzheimer's disease.
Embargo and press information about CTAD: https:/
Understanding clinical studies--Why do researchers do different kinds of clinical studies?: https:/
About the National Institute on Aging (NIA): NIA leads the U.S. federal government effort to conduct and support research on aging and the health and well-being of older people. Learn more about age-related cognitive change and neurodegenerative diseases via NIA's Alzheimer's Disease Education and Referral (ADEAR) Center website. For information about a broad range of aging topics, visit the main NIA website and stay connected.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.